摘要
目的探讨黄芪多糖联合常规方案用于2型糖尿病(T2DM)早期糖尿病肾病(DN)患者治疗当中的效果.方法纳入研究的对象为2021年1月-2021年12月就诊于宝安区中心医院的T2DM早期DN患者200例,患者按照就诊编号采用随机抽签的方式分为两组,分别为对照组与治疗组各100例,对照组采用常规方案治疗,治疗组则在对照组治疗的基础上联合黄芪多糖治疗;比较分析两组治疗后疗效及相关临床实验指标变化情况.结果治疗后,治疗组临床治疗总有效率(88.00%)显著高于对照组(69.00%),治疗组患者β2-微球蛋白(β2-MG)、尿微量白蛋白/尿肌酐(mALB/Ucr)、糖化血红蛋白(HbAlC)、空腹血糖(GLU)和餐后2h血糖值(2hBPG)实验指标水平较对照组低(P<0.05).结论黄芪多糖联合常规治疗T2DM早期DN患者,有助于改善患者病情,临床疗效比较显著,值得在临床上推广.
Objective To study the effect of astragalus polysaccharide combined with routine treatment in patients with type 2 diabetes(T2DM)early diabetic nephropathy(DN).Methods The subjects of this study were 200 patients with early T2DM DN who visited our hospital from January 2021 to December 2021.The patients were randomly divided into two groups according to the number of visits,100 cases in each group,the control group and the treatment group,while the control group was treated with conventional DN disease,and the treatment group was treated with astragalus polysaccharide on the basis of the control group.Results After treatment,the total effective rate of clinical treatment in the treatment group(88.00%)was significantly higher than that in the control group(69.00%),glycosylated hemoglobin(HbAIC),fasting blood glucose(GLU)and 2h postprandial blood glucose(2hBPG)were lower than those in the control group(P<0.05).Conclusion Astragalus polysaccharide combined with routine treatment of T2DM patients with early DN can not only help to improve the patient's condition,but also has a significant clinical effect,which is worthy of clinical promotion.
作者
颜维泽
林金钗
Yan Weize;Lin Jinchai(Fuyong People's Hospital,Baoan District,Shenzhen,Guangdong 518103,China;Baoan District Central Hospital,Shenzhen,Guangdong 518102,China)
出处
《首都食品与医药》
2023年第1期135-138,共4页
Capital Food Medicine
关键词
黄芪多糖
常规
联合
早期
糖尿病肾病
临床疗效
stragalus polysaccharide
routine
combination
early stage
diabetic nephropathy
clinical efficacy
